|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0040808,
umls-concept:C0079083,
umls-concept:C0205177,
umls-concept:C0205250,
umls-concept:C0205390,
umls-concept:C0246415,
umls-concept:C0278488,
umls-concept:C0302350,
umls-concept:C0728747,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-7
|
|
pubmed:abstractText |
Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BuyseMarcM,
pubmed-author:CrownJohnJ,
pubmed-author:EiermannWolfgangW,
pubmed-author:ForbesJohnJ,
pubmed-author:FumoleauPierreP,
pubmed-author:Jagiello-GruszfeldAgnieszkaA,
pubmed-author:MackeyJohn RJR,
pubmed-author:MartinMiguelM,
pubmed-author:Mrsic-KrmpoticZrinkaZ,
pubmed-author:PegramMark DMD,
pubmed-author:PienkowskiTadeuszT,
pubmed-author:PressMichael FMF,
pubmed-author:RivaAlessandroA,
pubmed-author:RocheHenriH,
pubmed-author:RolskiJanuszJ,
pubmed-author:SauterGuidoG,
pubmed-author:SlamonDennis JDJ,
pubmed-author:TaupinHenryH,
pubmed-author:ValeroVicenteV,
pubmed-author:von MinckwitzGunterG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
149-56
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21115860-Antibodies, Monoclonal,
pubmed-meshheading:21115860-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21115860-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21115860-Breast Neoplasms,
pubmed-meshheading:21115860-Carboplatin,
pubmed-meshheading:21115860-Disease-Free Survival,
pubmed-meshheading:21115860-Female,
pubmed-meshheading:21115860-Gene Amplification,
pubmed-meshheading:21115860-Humans,
pubmed-meshheading:21115860-Middle Aged,
pubmed-meshheading:21115860-Neoplasm Metastasis,
pubmed-meshheading:21115860-Receptor, erbB-2,
pubmed-meshheading:21115860-Taxoids
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
|
|
pubmed:affiliation |
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. vvalero@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
